Sacroileitis and peripheral arthropathy associated with ulcerative colitis: effect of infliximab on both articular and intestinal symptoms.
Infliximab has been proven to be an effective therapy in a miscellany of rheumatic diseases and has been approved for the treatment of moderate-to-severe Crohn's disease with an inadequate response to conventional therapy and for the management of enterocutaneous fistulas. Data about the role of infliximab in ulcerative colitis are still controversial. Here, we report a case of a patient with sacroileitis and peripheral arthropathy associated with left-sided ulcerative colitis who achieved a sustained clinical remission after infliximab therapy.
Lupascu
A
A
Department of Internal Medicine, Catholic University of Rome, Largo A. Gemelli 8, Rome 00168, Italy.
Armuzzi
A
A
De Pascalis
B
B
Carloni
E
E
Lauritano
E C
EC
Gasbarrini
A
A
Pola
P
P
Gasbarrini
A
A
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D012446:Sacroiliac Joint; D013585:Synovitis / Q000188:drug therapy* / Q000209:etiology
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab